Jonathan Rosenberg

Jonathan Rosenberg is a leading bladder cancer clinician-researcher at Memorial Sloan Kettering who has led the development of multiple FDA-approved therapies for urothelial carcinoma. He conducted key trials of enfortumab vedotin (Nectin-4 directed ADC) and sacituzumab govitecan that received FDA approval for urothelial cancer. His research has advanced the field of antibody-drug conjugates specifically in urothelial carcinoma. He has been a principal investigator in landmark cisplatin-containing and immunotherapy combination trials.